Wide Ranks

FULC

Fulcrum Therapeutics, Inc.

3.95

Top Statistics
Market Cap 213 M Forward PE -3.72 Revenue Growth 8990.90 %
Current Ratio 22.07 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins -24.79 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA 1.36 Enterprise / Revenue -0.5140 Price To Sales Trailing12 Months 2.61
Profitability
Profit Margins -24.79 % Operating Margins 65.61 %
Balance Sheet
Total Cash 273 M Total Cash Per Share 4.39 Total Debt 9 M
Total Debt To Equity 3.52 Current Ratio 22.07 Book Value Per Share 3.80
All Measures
Short Ratio 767.00 % Message Board Id finmb_376267397 Shares Short Prior Month 5 M
Return On Equity -0.0737 City Cambridge Uuid f8324037-ced6-3388-ab03-bdea45be2e3b
Previous Close 3.55 First Trade Date Epoch Utc 1 B Book Value 3.80
Beta 2.23 Total Debt 9 M Volume 1 M
Price To Book 1.04 Fifty Two Week Low 2.86 Total Cash Per Share 4.39
Total Revenue 81 M Shares Short Previous Month Date 1 B Target Median Price 4.00
Audit Risk 4 Max Age 86400 Recommendation Mean 2.75
Sand P52 Week Change 0.3133 Operating Margins 65.61 % Target Mean Price 5.29
Net Income To Common -20234000 Short Percent Of Float 0.0992 Implied Shares Outstanding 68 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 988060
Average Volume10days 988060 Total Cash 273 M Next Fiscal Year End 1 B
Revenue Per Share 1.32 Held Percent Insiders 0.0162 Ebitda Margins -37.83 %
Trailing PE 0.0000 Date Short Interest 1 B Most Recent Quarter 1 B
Share Holder Rights Risk 8 Regular Market Previous Close 3.55 Target Low Price 2.00
Gmt Off Set Milliseconds -18000000 Fifty Day Average 3.42 Open 3.60
Free Cashflow -6718750 State MA Dividend Yield 0.00 %
Return On Assets -0.0689 Time Zone Short Name EST Board Risk 6
Trailing Eps -0.2900 Day Low 3.58 Address1 26 Landsdowne Street
Shares Outstanding 53 M Compensation Risk 9 Price Hint 4
Target High Price 14.00 Website https://www.fulcrumtx.com 52 Week Change -0.1771
Average Volume 1 M Forward Eps -1.22 Recommendation Key hold
Compensation As Of Epoch Date 1 B Quick Ratio 2183.70 % Is_sp_500 False
Regular Market Day High 4.08 Profit Margins -24.79 % Debt To Equity 3.52
Fifty Two Week High 13.70 Day High 4.08 Shares Short 4 M
Regular Market Open 3.60 Industry Key biotechnology Earnings Growth 0.00 %
Enterprise To Revenue -0.5140 Revenue Growth 8990.90 % Shares Percent Shares Out 0.0797
Operating Cashflow -12449000 Currency USD Time Zone Full Name America/New_York
Market Cap 213 M Is_nasdaq_100 False Zip 02139
Quote Type EQUITY Industry Biotechnology Long Name Fulcrum Therapeutics, Inc.
Overall Risk 8 Regular Market Day Low 3.58 Held Percent Institutions 0.8970
Current Price 3.95 Enterprise To Ebitda 1.36 Financial Currency USD
Current Ratio 22.07 Gross Margins 9.02 % Industry Disp Biotechnology
Number Of Analyst Opinions 7 Country United States Float Shares 40 M
Two Hundred Day Average 7.06 Governance Epoch Date 1 B Enterprise Value -41979260
Price To Sales Trailing12 Months 2.61 Forward PE -3.72 Regular Market Volume 1 M
Ebitda -30880000 Exchange NGM
Go to Yahoo Finance Go to Seeking Alpha 
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States.

Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.

The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases.

It has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies; and Sanofi for the development and commercialization of losmapimod, an oral small molecule being investigated for the treatment of facioscapulohumeral muscular dystrophy.

Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.